Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Phase I taselisib results and a cell-free DNA assay

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.04.18
Views: 254

Dr José Baselga - Memorial Sloan Kettering Cancer Center, New York, USA

Dr Baselga speaks with ecancer at AACR 2018 about results from a phase I basket study of taselisib to treat locally advanced or metastatic solid tumours harbouring a PIK3CA mutation.

He highlights how these mutations occur in a host of sites throughout the body.

Dr Baslega also describes results from the development of a cell-free DNA assay, allowing for early detection and monitoring treatment response.

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence